Innoviva Return on Tangible Equity 2010-2024 | INVA

Current and historical return on tangible equity values for Innoviva (INVA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Innoviva Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2024-09-30 $0.07B $0.44B 14.78%
2024-06-30 $0.15B $0.43B 34.52%
2024-03-31 $0.18B $0.46B 46.70%
2023-12-31 $0.18B $0.43B 52.10%
2023-09-30 $0.05B $0.37B 16.12%
2023-06-30 $0.23B $0.30B 75.79%
2023-03-31 $0.23B $0.29B 67.19%
2022-12-31 $0.22B $0.29B 55.48%
2022-09-30 $0.29B $0.37B 65.47%
2022-06-30 $0.10B $0.46B 20.68%
2022-03-31 $0.19B $0.44B 40.35%
2021-12-31 $0.27B $0.53B 50.26%
2021-09-30 $0.31B $0.49B 56.41%
2021-06-30 $0.27B $0.39B 47.45%
2021-03-31 $0.25B $0.70B 43.38%
2020-12-31 $0.22B $0.61B 43.88%
2020-09-30 $0.22B $0.54B 48.65%
2020-06-30 $0.23B $0.49B 59.80%
2020-03-31 $0.19B $0.41B 59.11%
2019-12-31 $0.16B $0.34B 58.90%
2019-09-30 $0.38B $0.28B 168.99%
2019-06-30 $0.38B $0.25B 307.63%
2019-03-31 $0.40B $0.20B 1666.67%
2018-12-31 $0.40B $0.16B -499.68%
2018-09-30 $0.19B $-0.11B -105.70%
2018-06-30 $0.17B $-0.16B -80.10%
2018-03-31 $0.15B $-0.21B -60.25%
2017-12-31 $0.13B $-0.24B -48.86%
2017-09-30 $0.10B $-0.22B -33.47%
2017-06-30 $0.09B $-0.30B -27.22%
2017-03-31 $0.07B $-0.33B -20.31%
2016-12-31 $0.06B $-0.35B -16.32%
2016-09-30 $0.04B $-0.37B -10.58%
2016-06-30 $0.02B $-0.36B -5.18%
2016-03-31 $-0.01B $-0.36B 1.51%
2015-12-31 $-0.02B $-0.34B 6.56%
2015-09-30 $-0.04B $-0.32B 14.55%
2015-06-30 $-0.06B $-0.29B 18.95%
2015-03-31 $-0.11B $-0.26B 35.28%
2014-12-31 $-0.17B $-0.22B 76.47%
2014-09-30 $-0.20B $-0.41B 224.31%
2014-06-30 $-0.23B $-0.38B -275.08%
2014-03-31 $-0.20B $0.13B -104.28%
2013-12-31 $-0.17B $0.30B -92.27%
2013-09-30 $-0.15B $0.29B -101.85%
2013-06-30 $-0.14B $0.06B -116.81%
2013-03-31 $-0.14B $0.09B -91.95%
2012-12-31 $-0.02B $0.16B -13.77%
2012-09-30 $-0.02B $0.17B -34.16%
2012-06-30 $-0.02B $0.19B -163.27%
2012-03-31 $-0.01B $0.01B 18.08%
2011-12-31 $-0.12B $-0.09B 219.91%
2011-09-30 $-0.10B $-0.06B 268.49%
2011-06-30 $-0.09B $-0.04B 154.39%
2011-03-31 $-0.08B $-0.03B 105.99%
2010-12-31 $-0.08B $-0.02B 83.58%
2010-09-30 $-0.09B $-0.14B 61.16%
2010-06-30 $-0.09B $-0.13B 58.37%
2010-03-31 $-0.09B $-0.11B 55.97%
2009-12-31 $-0.09B $-0.19B 50.97%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.122B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.145B 74.49
Novo Nordisk (NVO) Denmark $464.190B 33.48
Johnson & Johnson (JNJ) United States $345.687B 14.02
AbbVie (ABBV) United States $303.100B 15.95
Merck (MRK) United States $251.749B 16.73
AstraZeneca (AZN) United Kingdom $199.805B 17.00
Novartis AG (NVS) Switzerland $197.798B 13.15
Pfizer (PFE) United States $146.038B 9.99
Sanofi (SNY) $120.547B 10.92